Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antidepressant
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associatedWith |
increased risk of suicidal thoughts
|
| gptkbp:availableIn |
tablet
capsule liquid |
| gptkbp:brand |
gptkb:Sarafem
fluoxetine |
| gptkbp:chemicalFormula |
liver
|
| gptkbp:clinicalTrials |
depression treatment
OCD treatment PMDD treatment bulimia treatment panic disorder treatment |
| gptkbp:contraindication |
gptkb:MAO_inhibitors
pimozide thioridazine |
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:dosageForm |
oral
|
| gptkbp:drugInterdiction |
prescription only
|
| gptkbp:endOfLife |
1 to 4 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Prozac
|
| gptkbp:interactsWith |
NSAIDs
warfarin other antidepressants |
| gptkbp:isOpenToPublic |
norfluoxetine
|
| gptkbp:isRecognizedFor |
pregnant women
children under 18 breastfeeding women |
| gptkbp:lastProduced |
1987
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:United_Kingdom gptkb:United_States |
| gptkbp:sideEffect |
anxiety
nausea drowsiness insomnia dry mouth sexual dysfunction |
| gptkbp:symptoms |
dizziness
fatigue nausea irritability |
| gptkbp:triggerType |
selective serotonin reuptake inhibitor
|
| gptkbp:type |
fluoxetine hydrochloride
|
| gptkbp:usedFor |
obsessive-compulsive disorder
major depressive disorder bulimia nervosa premenstrual dysphoric disorder panic disorder |